NGAL has been examined as a clinical marker in several clonal disorders (particularly in chronic myeloid leukemia (CML), with a purported link with tyrosine kinase breakpoint cluster region-Abelson (BCR-ABL)), though its predictive and prognostic value is still uncertain [54]. Here, LCN2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.